Inactive Instrument

Highlights Can Fite Biopharma Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0010944739

Highlights

Unlock all the news: Be the first to know and act before the market!

Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	Jul. 01	CI
Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix	Jun. 28	CI
Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver	Jun. 24	CI
Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	Jun. 10	CI
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study	Jun. 05	CI
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	May. 09	CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	May. 06	CI
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	Apr. 03	CI
Can-Fite Biopharma Ltd. Announces Clinical Update	Mar. 28	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	Mar. 11	CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	Feb. 28	CI
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	Jan. 30	CI
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial	Jan. 29	CI
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action	Dec. 20	CI
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	Dec. 18	RE
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson	Dec. 18	CI
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients	Dec. 04	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 30	CI
Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson	Nov. 21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Can Fite Biopharma Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0010944739

Highlights

Filters